Counterfeit Herceptin finds its way into European supply chain

Vials from nine batches of Roche's (RHHBY) top-selling drug allegedly stolen in Italy have been tampered with and reintroduced into the European market. Adulterated vials have turned up in Germany, Finland and the U.K. Some do not contain any trastuzumab at all while others have been diluted.

There are no reports of harm to patients from the fakes. The company is recalling the suspect vials as a precaution.

Herceptin sales last year were $6.9B.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs